AACR Virtual Annual Meeting II (Poster Session)
The AACR Foundation is the philanthropic arm of the American Association for Cancer Research (AACR). The Foundation supports the groundbreaking work of the AACR and its more than 47,000 members on the front lines of the global effort to eradicate cancer. The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.
In AACR 2020 Annual Meeting, Biocytogen has over 10 posters on topics such as in vivo efficacy studies for anti-tumor therapeutics using our unique humanized mice models, as well as antibody discovery using RenMab Mouse. Abstracts and e-posters are available on AACR website. If you want to download the full PDFs, please go to our resource hub.
|Abstract #||Poster Title (Click to download)||Session Category|
|522||Optimization of novel anti-4-1BB antibodies on Biocytogen’s in vivo drug screening platform||Experimental and Molecular Therapeutics|
|589||Immune biomarker profiling and safety evaluation response to 4-1BB antibody (Urelumab) in humanized 4-1BB mice||Experimental and Molecular Therapeutics|
|939||Evaluating anti-PD-1/4-1BB combination therapy: In vivo efficacy with humanized double knock-in mice||Immunology|
|432||Development of a novel engineered B2M mouse strain on B-NDG background that specifically eliminates MHC I expression while retaining normal FcRn-mediated antibody retention||Tumor Biology|
|1632||Long-term maintenance of human mature NK cells from hCD34+HSCs engraftment supported by immune humanized B-NDG hIL15 mice||Tumor Biology|
|3368||A novel anti-CTLA-4 antibody with potent anti-tumor activity emerged using humanized CTLA-4 mouse model||Immunology|
|3369||Rapid screening of novel OX40 agonistic antibodies for cancer immunotherapy||Immunology|
|5618||Evaluating anti-IL-2Ra in vivo efficacy on humanized knock-in mice||Immunology|
|5050||Novel TNFR2 humanized mouse model for human TNFR2 antibody evaluation||Tumor Biology|
|5051||RenMab Mouse: A leading platform for fully human antibody generation||Tumor Biology|
|6307||In vivo drug screening platform accelerates anti-hCD40 antibody drug discovery||Experimental and Molecular Therapeutics|